Cytomegalovirus seronegative platelets and leukocyte-poor red blood cells from random donors can prevent primary cytomegalovirus infection after bone marrow transplantation.
The effect of a deliberate transfusion policy for prevention of primary cytomegalovirus (CMV) infection, consisting of leukocyte-poor red blood cells from random donors and platelets from CMV-negative donors, was studied in 29 CMV-negative negative recipients of an allogeneic (from CMV-negative donors) or autologous bone marrow transplant. All transplant recipients remained CMV-negative with this approach. Such a policy depends on the availability of CMV-negative platelet donors. Siblings from CMV-negative marrow transplantation candidates appeared to be more often CMV-negative than siblings from CMV-positive transplantation candidates (77% versus 34%, p less than 0.001). Selection of CMV-negative blood bank donors for transfusion of blood products is also easy to perform. As a consequence, CMV-negative marrow transplant recipients have a good chance of receiving CMV-negative marrow transplants and blood products and primary CMV infection can thus be prevented by this transfusion policy.
Verdonck
L F
LF
Department of Haematology, University Hospital, Utrecht, The Netherlands.
de Graan-Hentzen
Y C
YC
Dekker
A W
AW
Mudde
G C
GC
de Gast
G C
GC
D000741:Anemia, Aplastic / Q000628:therapy; D000914:Antibodies, Viral / Q000032:analysis; D001771:Blood Banks; D001782:Blood Donors; D016026:Bone Marrow Transplantation; D003586:Cytomegalovirus Infections / Q000175:diagnosis / Q000517:prevention & control*; D017707:Erythrocyte Transfusion; D006801:Humans; D007938:Leukemia / Q000628:therapy; D009894:Opportunistic Infections / Q000517:prevention & control*; D017713:Platelet Transfusion; D012698:Serologic Tests
D000914:Antibodies, Viral